Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Allergen Challenge Trial di IRL201104 nella rinite allergica stagionale

17 settembre 2026 aggiornato da: Revolo Biotherapeutics

Uno studio di sfida sugli allergeni di fase 2a, randomizzato, in doppio cieco, controllato con placebo, con progettazione parallela di 6 dosi ripetute di IRL201104 in partecipanti adulti con rinite allergica stagionale.

The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

63

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • London, Regno Unito
        • Hammersmith Medicines Research
      • London, Regno Unito
        • King's College London

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Male or female, 18 to 65 years old, inclusive, at time of signing the informed consent form (ICF).

  2. Body mass index within the range 19 to 30 kg/m2.

  3. A clinical history of grass pollen-induced allergic rhinitis for at least 2 years with peak symptoms in May, June, or July.

  4. A clinical history of moderate to severe rhinitis symptoms interfering with usual daily activities or with sleep as defined according to the ARIA classification of rhinitis (Bousquet, Khaltaev et al 2008)

  5. A clinical history of rhinitis for at least 2 years requiring treatment with either antihistamines or nasal corticosteroids during the grass pollen season.

  6. Positive skin prick test response, defined as wheal diameter greater than or equal to 5 mm, to Phleum pratense.

  7. Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L), against Phleum pratense.

  8. A positive response to the nasal allergen challenge with Phleum pratense, defined as an increase in TNSS greater than or equal to 5 points.

  9. Agree to follow the contraception requirements of the trial as described in Appendix 7.

    Female participants must agree to use highly effective contraception as described in Appendix 7, or must be of non-childbearing potential. A woman is considered to be of non-childbearing potential if she meets one of the following criteria:

    1. post-menopausal (amenorrhea for at least 12 months, and follicle-stimulating hormone [FSH] tests at screening confirms post-menopausal status)
    2. has no uterus, ovaries or fallopian tubes. c. documentation of non-childbearing potential from a reproductive specialist.
  10. The ability to give informed consent and comply with study procedures.

  11. Venous access as appropriate for IV dosing, as judged by the investigator or delegate.

Exclusion Criteria:

  1. A prebronchodilator forced expiry volume in 1 second (FEV1) less than 70% of the predicted value at the screening baseline visit.
  2. Clinical history of persistent asthma requiring regular inhaled corticosteroids for > 4 weeks per year outside of the grass pollen season.
  3. Clinical history of moderate - severe allergic rhinitis, according to the ARIA classification, caused by a perennial allergen to which the participant is regularly exposed.
  4. Clinical history of moderate-severe allergic rhinitis, according to the ARIA classification, caused by tree pollen (those with mild intermittent symptoms not requiring regular treatment may be included).
  5. History of emergency visit or hospital admission for asthma in the previous 12 months.
  6. History of chronic obstructive pulmonary disease.
  7. History of significant recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment.
  8. History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, ear pain, pressure, or fullness.
  9. History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency.
  10. At randomization, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media, or other relevant infectious process; serous otitis media is not an exclusion criterion. Participants may be re-evaluated for eligibility after symptoms resolve.
  11. Active malignancy at randomization.
  12. Any tobacco smoking within the last 6 months or a history of greater than or equal to 10 pack years.
  13. Previous treatment by immunotherapy with grass pollen allergen within the previous 5 years.
  14. History of bleeding disorders or treatment with anticoagulation therapy.
  15. History of anti-IgE monoclonal antibody treatment.
  16. Ongoing systemic immunosuppressive treatment.
  17. History of intolerance to the study therapy, rescue medications, or their excipients.
  18. Pregnant or lactating women. For women of childbearing potential, a positive serum or urine pregnancy test.
  19. The use of any investigational drug within 30 days of the screening visit.
  20. The presence of any medical condition that the investigator deems incompatible with participation in the study.
  21. Moderate or severe renal impairment (eGFR <60 mL/min/1.73 m2) or end stage renal disease.

23. Known or suspected immunosuppression, including history of invasive opportunistic infections (eg, history of or active tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immunocompromised status, as judged by the investigator. 24. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the volunteer. 25. Clinical contraindication to intradermal challenge (IDC), skin prick test (SPT), skin prick titration (SPT), or nasal allergen challenge (NAC), to include:

  1. Previous anaphylactic reaction to grass pollen or extract excipients
  2. Acute inflammation of the nose or paranasal sinuses
  3. Severe and uncontrolled bronchial asthma or chronic obstructive pulmonary disease
  4. Systemic immunotherapy
  5. A generalised dermatological condition rendering it impracticable to perform SPT or IDC on unaffected skin.
  6. Severe dermatographism
  7. Unable to cease antihistamines/other interfering drugs (i.e. antidepressants)
  8. Concomitant use of beta-blockers

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1: IRL201104

IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70

lyophilised powder for reconstitution for IV dosing

Comparatore placebo: Arm 2: Placebo

Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70

Matching placebo for IRL201104

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The mean diameter of the Intradermal Challenge (IDC) Late Phase Response (LPR) on Day 84 measured 8 hours post-challenge after 10 weeks of treatment with IRL201104 compared with placebo.
Lasso di tempo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The largest diameter (mm) of the IDC Early Phase Response (EPR) at 30 minutes after 10 weeks of treatment with IRL201104 compared with placebo
Lasso di tempo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Skin prick test EPR endpoint titration of Grass Soluprick after 10 weeks of treatment with IRL201104 compared with placebo.
Lasso di tempo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
The weighted average of the TNSS per hour following NAC after challenge on Day 1 and day 84 of treatment with IRL201104 compared with placebo.
Lasso di tempo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Percent change in peak nasal inspiratory flow (PNIF) after the NAC on day 1 and day 84 of treatment with IRL201104 compared with placebo.
Lasso di tempo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Concentration of IRL20114 levels.
Lasso di tempo: Day 56

IRL201104 plasma levels will be summarized for each blood sample draw timepoint

Day 56
Vital Signs: Blood pressure
Lasso di tempo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: Pulse rate
Lasso di tempo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: oral body temperature
Lasso di tempo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: respiration rate
Lasso di tempo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Treatment Emergent Adverse Events
Lasso di tempo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Incidence of treatment-emergent antidrug antibody (ADA) responses
Lasso di tempo: Day 84

Tabulated and presented as the number and percentage of participants exhibiting the response within each treatment group

Day 84
Safety Laboratory: Biochemistry
Lasso di tempo: Day 84

Glucose, liver function tests, urea, and electrolytes will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.

Day 84
Safety Laboratory: Haematology
Lasso di tempo: Day 84

Full blood count variables will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.

Day 84

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Anoshie Ratnayake, MD, Revolo Biotherapeutics

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 novembre 2021

Completamento primario (Effettivo)

27 marzo 2023

Completamento dello studio (Effettivo)

27 marzo 2023

Date di iscrizione allo studio

Primo inviato

30 settembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

18 ottobre 2021

Primo Inserito (Effettivo)

28 ottobre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

21 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi